Combines research and clinical perspectives on strategies to pair radiotherapy with immunotherapy for triple-negative breast cancer, highlighting study design and translational questions.
Key Takeaways
- Immune checkpoint inhibitor monotherapy shows limited efficacy in advanced triple-negative breast cancer
- Radiotherapy can remodel the tumor immune microenvironment and potentially synergize with immunotherapy
- Clinical studies are early and small, highlighting challenges in dosing, sequencing, toxicity, and patient selection